Literature DB >> 15768351

Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries.

Jens Reimer1, Bernd Schulte, Xavier Castells, Ingo Schafer, Susanne Polywka, Dagmar Hedrich, Lucas Wiessing, Christian Haasen, Markus Backmund, Michael Krausz.   

Abstract

Treatment guidelines are considered to be an important tool in steering patients to medical treatment. This study was conducted to analyze guidelines for the treatment of hepatitis C virus (HCV) infection in injection drug users (IDUs) in the European Union (EU) countries as a component of treatment access. National and international databases, expert contacts, professional societies, and health administrations were approached to acquire guidelines. According to their quality standard, guidelines were divided into expert opinions, semiofficial guidelines, official guidelines, and consensus processes. Recommendations for the treatment of HCV infection in IDUs vary substantially, from lack of recommendations and outright treatment disapproval to recommendations for treatment under specified circumstances. Recent guidelines that apply qualified process procedures that include literature research tend to be more permissive. Qualified guideline processes in each EU country and subsequently renewed pan-European guidelines are needed.

Entities:  

Mesh:

Year:  2005        PMID: 15768351     DOI: 10.1086/427456

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

Review 1.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

2.  Hepatitis C, illicit drug use and public health: does Canada really have a viable plan?

Authors:  Benedikt Fischer; Kate Kalousek; Jürgen Rehm; Jeff Powis; Mel Krajden; Jens Reimer
Journal:  Can J Public Health       Date:  2006 Nov-Dec

3.  Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?

Authors:  Ilias Gountas; Vana Sypsa; Olga Anagnostou; Natasha Martin; Peter Vickerman; Evangelos Kafetzopoulos; Angelos Hatzakis
Journal:  Addiction       Date:  2017-02-17       Impact factor: 6.526

4.  10-year trends in the diagnosis and treatment of hepatitis C and concomitant mental health disorders: 1995 to 2005.

Authors:  Barbara P Yawn; Liliana Gazzuola Rocca; Peter C Wollan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 5.  Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review.

Authors:  Viktor Mravčík; Lisa Strada; Josef Stolfa; Vladimir Bencko; Teodora Groshkova; Jens Reimer; Bernd Schulte
Journal:  Patient Prefer Adherence       Date:  2013-10-17       Impact factor: 2.711

6.  A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia.

Authors:  Mojca Maticic
Journal:  BMC Infect Dis       Date:  2014-09-19       Impact factor: 3.090

Review 7.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

8.  High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).

Authors:  Benjamin Wenz; Stine Nielsen; Martyna Gassowski; Claudia Santos-Hövener; Wei Cai; R Stefan Ross; Claus-Thomas Bock; Boris-Alexander Ratsch; Claudia Kücherer; Norbert Bannert; Viviane Bremer; Osamah Hamouda; Ulrich Marcus; Ruth Zimmermann
Journal:  BMC Public Health       Date:  2016-09-05       Impact factor: 3.295

9.  HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.

Authors:  N K Martin; G R Foster; J Vilar; S Ryder; M E Cramp; F Gordon; J F Dillon; N Craine; H Busse; A Clements; S J Hutchinson; A Ustianowski; M Ramsay; D J Goldberg; W Irving; V Hope; D De Angelis; M Lyons; P Vickerman; M Hickman
Journal:  J Viral Hepat       Date:  2014-10-07       Impact factor: 3.728

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.